OPT Opthea Ltd.: Pangali EV/EBITDA

The pricing characteristics on the GURU.Markets platform, where the EV/EBITDA ratio is , complement the data regarding sustainable drug development and bioethical compliance at Opthea Limited (OPT). Opthea Limited (OPT) minimizes risks by developing a therapy to combat retinal degeneration in the elderly. However, business success depends on the final test results of the key drug, which creates a high probability of sharp price volatility.

The EV/EBITDA multiple compares the total enterprise value of a business, including net debt, with its operating profit before taxes, depreciation, and amortization. By analyzing the dynamic EV/EBITDA value of a company, an investor determines the payback period for assets excluding financial leverage. For Opthea Limited (OPT), this indicator is critical as it reflects the market valuation of sozinibercept's potential in AMD therapy relative to current operating expenses within the biopharmaceutical sector.